Prosecution Insights
Last updated: May 29, 2026

Medshine Discovery Inc.

5 pending office actions • 4 art units • 5 examiners • 0 of 5 (0%) have an AI response strategy ready • 10 patents granted in the last 365 days

Portfolio Summary

5
Total Pending OAs
4
Non-Final OAs
1
Final Rejections
0
Advisory / Quayle

Response Deadline Pressure

Based on the USPTO statutory response window for each pending office action. 5 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.

3
Overdue
0
Due this week
1
Due this month
0
Due in next 60 days
1
Due later

Deadline Fire Line

Every pending office action with a known statutory deadline, placed on a days-until-due axis. Dots left of Today are overdue; the further right, the more runway. Cases that share a deadline window stack vertically. 5 of the docket's apps have a known mailing date.

-30dToday30d60d90d120d
Overdue (3)Due ≤ 30 days (1)Due later (1)

Case Difficulty Mix

Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.

0
Hard (0%)
1
Medium (20%)
3
Easy (60%)
1
Unknown (20%)

Rejection Statute Mix

BucketCases
§102 only1 (20%)
§112 only3 (60%)
No statute on record1 (20%)

Industry Mix

How the docket's pending cases split across USPTO tech-center bands.

5
Life Sciences
100% of docket
0
Information Tech
0% of docket
0
Communications
0% of docket
0
Semiconductors
0% of docket
0
Mechanical / Eng
0% of docket
0
Business / Other
0% of docket

Time-on-OA Estimate

Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.

50 h
Manual time on pending OAs
10 h
Time saved (low, 20%)
18 h
Time saved (mid, 35%)
0.4 wks
FTE-weeks freed (mid)

Top Examiners on this docket

ExaminerApps on this docketAllow rateInterview lift
COUGHLIN, MATTHEW P 1 71.3% +11.8%
FETTEROLF, BRANDON J 1 49.5% +14.6%
MOTEVALLI, OROD 1
HABTE, KAHSAY 1 84.9% +7.3%
SHIAO, YIH-HORNG 1 72.6% +75.6%

Quick Wins (1)

Cases in front of an examiner with an allow rate of 80%+ where the difficulty is Easy or Medium. The top 1 ordered by deadline are shown.

App #TitleExaminerDue in
18263702 SUBSTITUTED PYRIDAZINE PHENOL DERIVATIVES HABTE, KAHSAY 62d

Interview Candidates (3)

Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 3 ordered by deadline are shown.

App #TitleExaminerDue in
18001429 CONJUGATE GROUP AND CONJUGATE SHIAO, YIH-HORNG 59d overdue
18550468 6-CARBAMATE SUBSTITUTED HETEROARYL RING DERIVATIVES FETTEROLF, BRANDON J 16d overdue
18569867 BENZOXAZINONE DERIVATIVES COUGHLIN, MATTHEW P 11d overdue

Top Art Units

Art UnitApps
1626 2
1628 1
1624 1
1691 1

Pending Office Actions

App #TitleExaminerArt UnitStatutesStatusDue inAIFiled
18569867 BENZOXAZINONE DERIVATIVES COUGHLIN, MATTHEW P 1626 §112 Non-Final OA 11d overdue Pending Dec 13, 2023
18550468 6-CARBAMATE SUBSTITUTED HETEROARYL RING DERIVATIVES FETTEROLF, BRANDON J 1626 §112 Non-Final OA 16d overdue Pending Sep 14, 2023
18549366 BICYCLIC PHENOL COMPOUNDS AND USE THEREOF MOTEVALLI, OROD 1628 §112 Non-Final OA 21d Pending Sep 07, 2023
18263702 SUBSTITUTED PYRIDAZINE PHENOL DERIVATIVES HABTE, KAHSAY 1624 §102 Non-Final OA 62d Pending Jul 31, 2023
18001429 CONJUGATE GROUP AND CONJUGATE SHIAO, YIH-HORNG 1691 Other Final Rejection 59d overdue Pending Dec 09, 2022

Managing Medshine Discovery Inc.'s Patent Portfolio?

IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.

Start Free Trial

Sign in with your work email

Enter your email to receive a magic link. No password needed.

Personal email addresses (Gmail, Yahoo, etc.) are not accepted.

Free tier: 3 strategy analyses per month